PURDUE INNOVATES | Office of Technology Commercialization

MODIFIED Discovery of Potent Protease Inhibitors for Covid-19 Treatment using Specifically Design Novel bis-amide Derivatives

A new class of noncovalent functionalized bis-amide inhibitors demonstrates potent antiviral properties against SARS-CoV-2, offering an improved therapeutic option for Covid-19 treatment and pandemic control.

Researchers at Purdue University have developed a new class of noncovalent functionalized bis-amide inhibitors for treatment of Covid-19.

There remains an ongoing global health pandemic which has now affected over 170 million people to date and there is no available therapeutic option. The compounds developed by Purdue researchers in this disclosure are newer modified versions of bis-amide derivatives that have demonstrated potent inhibitory effect on SARS-CoV-2 enzyme, 3CLpro. These inhibitors have been evaluated in immunocytochemical and cellular assays against Covid-19 infections.

Advantages:

-Potent Covid-19 Antiviral Properties

-Improved Drug-Like Features

Potential Applications:

-Treatment of SARS-CoV-2

-Pharmaceutical Research and Development

-Pandemic Control

Technology Validation:

The bis-amide compounds potently inhibited SARS-CoV-2 in in vitro studies and immunocytochemistry assays.

Technology ID
2021-GHOS-69206

Category
Pharmaceuticals/Drug Discovery & Development
Pharmaceuticals/Small Molecule Therapeutics
Pharmaceuticals/Research Tools & Assays

Authors
Arun K Ghosh
Andrew D Mesecar
Hiroaki Mitsuya

Further information
Joe Kasper
JRKasper@prf.org

Nathan Smith
nesmith@prf.org

View online

TRL: 3

Intellectual Property:

Provisional-Gov. Funding, 2020-12-01, United States | PCT-Gov. Funding, 2021-11-30, WO | NATL-Patent, 2023-05-31, United States

Keywords: bis-amide inhibitors, noncovalent functionalized, Covid-19 treatment, SARS-CoV-2, 3CLpro inhibitor, antiviral properties, drug-like features, pharmaceutical research, pandemic control, immunocytochemical assays